About CERo Therapeutics Holdings, Inc.
https://www.cero.bioCERo Therapeutics Holdings, Inc., an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead program in hematologic malignancies targets an Eat Me signal upregulated on B cell and myeloid tumors. The company is based in South San Francisco, California.
CEO
Christopher Ehrlich
Compensation Summary
(Year )
Ratings Snapshot
Rating : B-
Price Target
Institutional Ownership
COWEN AND COMPANY, LLC
Shares:737.17K
Value:$4.5K
CLEAR STREET GROUP INC.
Shares:461.65K
Value:$2.82K
ATALAYA CAPITAL MANAGEMENT LP
Shares:424.87K
Value:$2.59K
Summary
Showing Top 3 of 31
About CERo Therapeutics Holdings, Inc.
https://www.cero.bioCERo Therapeutics Holdings, Inc., an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead program in hematologic malignancies targets an Eat Me signal upregulated on B cell and myeloid tumors. The company is based in South San Francisco, California.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $0 | $4.36M ▼ | $-11.51M ▼ | 0% | $-9.1 ▲ | $-4.36M ▲ |
| Q2-2025 | $0 | $4.72M ▼ | $-5.42M ▼ | 0% | $-61.71 ▼ | $-5.16M ▼ |
| Q1-2025 | $0 ▼ | $4.95M ▲ | $-5.11M ▼ | 0% ▼ | $-3.18 ▼ | $-4.84M ▼ |
| Q4-2024 | $1.16M ▲ | $2.38M ▼ | $1.24M ▲ | 107.01% ▲ | $0.56 ▲ | $1.55M ▲ |
| Q3-2024 | $0 | $4.4M | $-4.23M | 0% | $-17.02 | $-4.4M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $2.02M ▼ | $3.91M ▼ | $8.45M ▲ | $-4.54M ▼ |
| Q2-2025 | $3.8M ▼ | $6.2M ▼ | $7.84M ▼ | $-1.63M ▼ |
| Q1-2025 | $5.2M ▲ | $7.99M ▲ | $8.32M ▲ | $-329.39K ▲ |
| Q4-2024 | $3.33M ▼ | $6.21M ▼ | $8.1M ▼ | $-1.89M ▲ |
| Q3-2024 | $3.38M | $6.49M | $10.19M | $-3.7M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-4.86M ▲ | $-3.21M ▲ | $500K ▲ | $1.42M ▼ | $-1.28M ▲ | $-3.21M ▲ |
| Q2-2025 | $-5.42M ▼ | $-4.62M ▼ | $0 | $2.72M ▼ | $-1.9M ▼ | $-4.62M ▼ |
| Q1-2025 | $-5.11M ▼ | $-4.45M ▼ | $0 ▲ | $6.32M ▲ | $1.88M ▲ | $-4.45M ▼ |
| Q4-2024 | $-1.05M ▼ | $-1.54M ▲ | $-4 ▼ | $1.49M ▼ | $-53.14K ▲ | $4.15M ▲ |
| Q3-2024 | $-4.23K | $-2.76M | $0 | $2.49M | $-266.82K | $-1.32M |
CEO
Christopher Ehrlich
Compensation Summary
(Year )
Ratings Snapshot
Rating : B-
Price Target
Institutional Ownership
COWEN AND COMPANY, LLC
Shares:737.17K
Value:$4.5K
CLEAR STREET GROUP INC.
Shares:461.65K
Value:$2.82K
ATALAYA CAPITAL MANAGEMENT LP
Shares:424.87K
Value:$2.59K
Summary
Showing Top 3 of 31